Peptide Therapy Market 2033: $106B Forecast, 10.8% CAGR

Multiple independent market research reports converge on a peptide therapeutics market trajectory of roughly $38 billion in 2023 growing to approximately $106 billion by 2033. The compound annual growth rate implied is approximately 10.8%, which places peptide therapeutics among the fastest-growing therapeutic modality categories in the broader pharmaceutical industry [1]. Different analyst houses publish slightly different point estimates, but the order of magnitude and the double-digit CAGR are consistent across the major 2024-2026 reports.

Peptide market forecasts combine three input layers: (1) currently marketed peptide drug revenue, (2) pipeline-adjusted projections for late-stage assets weighted by probability of technical and regulatory success, and (3) macro variables including reimbursement shifts, manufacturing capacity, and pricing pressure. The 2023-2033 window captures both the ongoing GLP-1 commercial ramp and the first waves of peptide-based oncology approvals [2].

Forecast uncertainty is asymmetric. Downside risk is dominated by GLP-1 pricing pressure under Medicare and payer negotiation, while upside risk is dominated by successful launch of oral GLP-1 small molecules and obesity- and cardiovascular-outcome-driven label expansion.

GLP-1 receptor agonists have become the single largest category within peptide therapeutics. Semaglutide (Novo Nordisks Ozempic / Wegovy / Rybelsus) and tirzepatide (Eli Lillys Mounjaro / Zepbound, a GIP/GLP-1 dual agonist) have together crossed tens of billions of dollars in annual revenue and continue to expand through cardiovascular and cardiorenal label extensions [3].

• Semaglutide: market leader in GLP-1 by revenue (oral and injectable formulations)
• Tirzepatide: GIP/GLP-1 dual agonist, fastest-growing in the class
• Retatrutide: GLP-1/GIP/glucagon triple agonist in Phase 3 (Eli Lilly)
• Survodutide: GLP-1/glucagon dual agonist in Phase 3 (Boehringer Ingelheim, Zealand)
• Orforglipron: oral non-peptide small molecule GLP-1 RA (Eli Lilly) approved in 2026

Three sponsors dominate the commercial and late-stage pipeline share of the peptide therapeutics market [4]:

• Novo Nordisk: semaglutide franchise, CagriSema (cagrilintide + semaglutide), amycretin
• Eli Lilly: tirzepatide, retatrutide, orforglipron (non-peptide oral GLP-1), broader incretin portfolio
• Boehringer Ingelheim: survodutide in partnership with Zealand Pharma; additional metabolic peptide assets

Beyond the top three, peptide portfolios at Amgen (MariTide), Roche, Pfizer, Structure Therapeutics, Viking Therapeutics, and others contribute to the broader pipeline. Oncology peptide assets at companies including BioNTech, Moderna, and specialized peptide-vaccine developers add a second growth vector less correlated with the metabolic category.

Injectable formulations continue to dominate peptide therapeutics by revenue share. The gradual expansion of oral peptide technologies (oral semaglutide using SNAC permeation enhancer, orforglipron as a non-peptide oral GLP-1 mimetic) is reshaping the long-term route mix [5]. Depot injectable formulations and implantable delivery systems remain important in oncology and endocrinology indications.

• Metabolic disease (diabetes, obesity, cardiometabolic): largest single segment
• Oncology: fastest-growing segment including peptide vaccines and targeted peptides
• Cardiovascular and renal: expanding via GLP-1 outcome trial label extensions
• Rare disease and endocrinology: stable baseline (octreotide, leuprolide, teriparatide)
• Inflammation and immunology: smaller but emerging (oral peptides, anti-IL-23 peptides)
• Infectious disease: smaller, specialty antimicrobial peptide programs

The main downside risk to the $106B 2033 figure is pricing pressure on GLP-1 assets: US Medicare negotiation, payer exclusion tactics, and international reference pricing all compress unit economics. The main upside risks are successful label expansion into cardiovascular, cardiorenal, metabolic-associated liver disease (MASH), Alzheimers, and addiction indications, plus successful commercialization of oral GLP-1 options [6].

• Pricing: Medicare negotiation under the Inflation Reduction Act
• Manufacturing: continued tight capacity for GLP-1 active pharmaceutical ingredients
• Oral competition: small-molecule GLP-1 agonists eroding injectable share
• Label expansion: cardiovascular, neurodegeneration, MASH
• Regulatory: compounded peptide restrictions and regulatory harmonization